Document Detail

PSA and second-line therapy of hormone refractory prostate carcinoma.
MedLine Citation:
PMID:  11316973     Owner:  NLM     Status:  MEDLINE    
The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was <4 ng/ml. Eight patients (33%) only had a subjective response. However, 75% of the patients with a PSA value <4 ng/ml had a subjective improvement. On the other hand, subjective response was 25% only in patients in whom PSA value decreased to <50% of the initial value but >4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient.
V Serretta; I Rizzo; G Contino; C Pavone; G Pomara; D Melloni; M Pavone-Macaluso
Related Documents :
21325853 - Low incidence of asymptomatic contrast-enhancing brain lesions in japanese patients wit...
2300353 - Preoperative serum tumor-associated antigen levels in women with pelvic masses.
6603133 - Uroradiologic manifestations of portal hypertension.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Urologia internationalis     Volume:  66     ISSN:  0042-1138     ISO Abbreviation:  Urol. Int.     Publication Date:  2001  
Date Detail:
Created Date:  2001-04-24     Completed Date:  2001-09-27     Revised Date:  2006-10-30    
Medline Journal Info:
Nlm Unique ID:  0417373     Medline TA:  Urol Int     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  131-4     Citation Subset:  IM    
Copyright Information:
Copyright 2001 S. Karger AG, Basel
Institute of Urology, University of Palermo, Palermo, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / blood*,  drug therapy*
Aged, 80 and over
Middle Aged
Prostate-Specific Antigen / blood*
Prostatic Neoplasms / blood*,  drug therapy*
Reg. No./Substance:
EC Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predictive value of radiological criteria for disintegration rates of extracorporeal shock wave lith...
Next Document:  Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated wit...